Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
17. lappuse
... dosage form suitable for use in self - medication by external application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The pramoxine hydrochloride ...
... dosage form suitable for use in self - medication by external application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The pramoxine hydrochloride ...
18. lappuse
... dosage unit . ( v ) The preparation is labeled with adequate directions for use in the tem- porary relief of the minor pains and discomforts that may occur a few days before and during the menstrual pe- riod . ( vi ) The dosages ...
... dosage unit . ( v ) The preparation is labeled with adequate directions for use in the tem- porary relief of the minor pains and discomforts that may occur a few days before and during the menstrual pe- riod . ( vi ) The dosages ...
19. lappuse
... dosage recommendations : ( a ) Clear warning statements against administration of the drug to children under 6 years of age or exceeding the recommended dosage , unless directed by a physician , and against driving a car or operating ...
... dosage recommendations : ( a ) Clear warning statements against administration of the drug to children under 6 years of age or exceeding the recommended dosage , unless directed by a physician , and against driving a car or operating ...
27. lappuse
... dosage formulation may be ob- tained by contacting the Food and Drug Administration , Center for Drug Evaluation and Research ( HFD - 420 ) , 5600 Fishers Lane , Rockville , MD 20857 . ( e ) Parts of the digoxin product label- ing ...
... dosage formulation may be ob- tained by contacting the Food and Drug Administration , Center for Drug Evaluation and Research ( HFD - 420 ) , 5600 Fishers Lane , Rockville , MD 20857 . ( e ) Parts of the digoxin product label- ing ...
28. lappuse
... dosage must be adjusted accord- ingly in patients with renal disease . NOTE : This applies also to potassium administra- tion should it become necessary . Electrical conversion of arrhythmias may require reduction of digoxin dosage ...
... dosage must be adjusted accord- ingly in patients with renal disease . NOTE : This applies also to potassium administra- tion should it become necessary . Electrical conversion of arrhythmias may require reduction of digoxin dosage ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning